Gene Therapy Market by Vectors (Non-viral (Oligonucleotides), Viral (Retroviral, Adeno-associated)), Indication (Cancer, Neurological, Hepatological Diseases, Duchenne Muscular Dystrophy), Delivery Method (In Vivo, Ex Vivo), Region – Global Forecast to 2027″, is projected to reach USD 17.2 billion by 2027 from USD 7.3 billion in 2022, at a CAGR of 18.6% between 2022 and 2027. Factors such as growing cases of cancer and neurological diseases, rising gene therapy product approvals, and increasing investment in research and development of gene therapies will drive the market growth. However, factors such as high cost associated with gene therapy are restraining the growth of this market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962
Browse in-depth TOC on “Gene Therapy Market”
165 – Tables
33 – Figures
159 – Pages
The non-viral vectors segment accounted for the largest share in the gene therapy market, by vector, during the forecast period.
Based on vectors, the gene therapy market is segmented into non-viral vectors and viral vectors. Non-viral vectors accounted for the larger market share in 2021. Less immunogenicity than viral vectors coupled with easier mass production of non-viral vectors are the major factors driving the growth of this segment.
The Neurological diseases segment accounted for the largest share of the indication segment in the gene therapy market in 2021.
Based on indication, the gene therapy market is segmented into neurological diseases, cancer, duchenne muscular dystrophy, hepatological diseases, and other indications. The neurological diseases segment accounted for the largest share of the gene therapy market in 2021. The largest share is attributed to growing burden of neurological diseases coupled with rising adoption of gene therapy for the treatment of neurological disorders.
The in vivo segment accounted for the larger share of the delivery method segment in the gene therapy market in 2021.
On the basis of delivery method, the gene therapy market is segmented into in vivo and ex vivo. In vivo segment accounted for the larger share in the gene therapy market as majority of the approved gene therapy products fall under in vivo delivery method.
Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=122857962
Key Market Players
Key players in the global gene therapy market include Biogen (US), Sarepta Therapeutics (US), Gilead Sciences, Inc. (US), Amgen, Inc. (US), Novartis AG (Switzerland), Orchard Therapeutics Plc (UK), Spark Therapeutics, Inc. (A Part Of ýF. Hoffmann-La Roche) (US), AGC Biologics (US), Anges, Inc. (Japan), Bluebird Bio, Inc. (US), Jazz Pharmaceuticals Plc (Ireland), Dynavax Technologies (US), Human Stem Cells Institute (Russia), Sibiono Genetech Co., Ltd. (China), Shanghai Sunway Biotech Co., Ltd. (China), Uniqure N.V. (Netherland), Gensight Biologics S.A. (France), Celgene Corporation (A Bristol-Myers Squibb Company) (US), Cellectis (France), Sangamo Therapeutics (US), Mustang Bio (US), AGTC (Applied Genetic Technologies Corporation) (US), and Poseida Therapeutics, Inc. (US).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=122857962
Browse Adjacent Market: 3D Bioprinting Market Research Reports & Consulting
Skin Health Foods Market / Dermatology Functional Foods Market by Indication (Skin Conditions, Anti-Aging, Anti-Allergy), Region (North America, Europe, Asia Pacific, Rest of the World), Regulatory Landscape, Pricing Analysis, COVID-19 Impact – Global Forecast to 2026
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/gene-therapy.asp